Cargando…
Targeting Macrophage Migration Inhibitory Factor in Acute Pancreatitis and Pancreatic Cancer
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine implicated in the pathogenesis of inflammation and cancer. It is produced by various cells and circulating MIF has been identified as a biomarker for a range of diseases. Extracellular MIF mainly binds to the cluster of different...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992011/ https://www.ncbi.nlm.nih.gov/pubmed/33776775 http://dx.doi.org/10.3389/fphar.2021.638950 |
_version_ | 1783669292404834304 |
---|---|
author | Wen, Yongjian Cai, Wenhao Yang, Jingyu Fu, Xianghui Putha, Lohitha Xia, Qing Windsor, John A. Phillips, Anthony R. Tyndall, Joel D. A. Du, Dan Liu, Tingting Huang, Wei |
author_facet | Wen, Yongjian Cai, Wenhao Yang, Jingyu Fu, Xianghui Putha, Lohitha Xia, Qing Windsor, John A. Phillips, Anthony R. Tyndall, Joel D. A. Du, Dan Liu, Tingting Huang, Wei |
author_sort | Wen, Yongjian |
collection | PubMed |
description | Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine implicated in the pathogenesis of inflammation and cancer. It is produced by various cells and circulating MIF has been identified as a biomarker for a range of diseases. Extracellular MIF mainly binds to the cluster of differentiation 74 (CD74)/CD44 to activate downstream signaling pathways. These in turn activate immune responses, enhance inflammation and can promote cancer cell proliferation and invasion. Extracellular MIF also binds to the C-X-C chemokine receptors cooperating with or without CD74 to activate chemokine response. Intracellular MIF is involved in Toll-like receptor and inflammasome-mediated inflammatory response. Pharmacological inhibition of MIF has been shown to hold great promise in treating inflammatory diseases and cancer, including small molecule MIF inhibitors targeting the tautomerase active site of MIF and antibodies that neutralize MIF. In the current review, we discuss the role of MIF signaling pathways in inflammation and cancer and summarize the recent advances of the role of MIF in experimental and clinical exocrine pancreatic diseases. We expect to provide insights into clinical translation of MIF antagonism as a strategy for treating acute pancreatitis and pancreatic cancer. |
format | Online Article Text |
id | pubmed-7992011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79920112021-03-26 Targeting Macrophage Migration Inhibitory Factor in Acute Pancreatitis and Pancreatic Cancer Wen, Yongjian Cai, Wenhao Yang, Jingyu Fu, Xianghui Putha, Lohitha Xia, Qing Windsor, John A. Phillips, Anthony R. Tyndall, Joel D. A. Du, Dan Liu, Tingting Huang, Wei Front Pharmacol Pharmacology Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine implicated in the pathogenesis of inflammation and cancer. It is produced by various cells and circulating MIF has been identified as a biomarker for a range of diseases. Extracellular MIF mainly binds to the cluster of differentiation 74 (CD74)/CD44 to activate downstream signaling pathways. These in turn activate immune responses, enhance inflammation and can promote cancer cell proliferation and invasion. Extracellular MIF also binds to the C-X-C chemokine receptors cooperating with or without CD74 to activate chemokine response. Intracellular MIF is involved in Toll-like receptor and inflammasome-mediated inflammatory response. Pharmacological inhibition of MIF has been shown to hold great promise in treating inflammatory diseases and cancer, including small molecule MIF inhibitors targeting the tautomerase active site of MIF and antibodies that neutralize MIF. In the current review, we discuss the role of MIF signaling pathways in inflammation and cancer and summarize the recent advances of the role of MIF in experimental and clinical exocrine pancreatic diseases. We expect to provide insights into clinical translation of MIF antagonism as a strategy for treating acute pancreatitis and pancreatic cancer. Frontiers Media S.A. 2021-03-11 /pmc/articles/PMC7992011/ /pubmed/33776775 http://dx.doi.org/10.3389/fphar.2021.638950 Text en Copyright © 2021 Wen, Cai, Yang, Fu, Putha, Xia, Windsor, Phillips, Tyndall, Du, Liu and Huang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wen, Yongjian Cai, Wenhao Yang, Jingyu Fu, Xianghui Putha, Lohitha Xia, Qing Windsor, John A. Phillips, Anthony R. Tyndall, Joel D. A. Du, Dan Liu, Tingting Huang, Wei Targeting Macrophage Migration Inhibitory Factor in Acute Pancreatitis and Pancreatic Cancer |
title | Targeting Macrophage Migration Inhibitory Factor in Acute Pancreatitis and Pancreatic Cancer |
title_full | Targeting Macrophage Migration Inhibitory Factor in Acute Pancreatitis and Pancreatic Cancer |
title_fullStr | Targeting Macrophage Migration Inhibitory Factor in Acute Pancreatitis and Pancreatic Cancer |
title_full_unstemmed | Targeting Macrophage Migration Inhibitory Factor in Acute Pancreatitis and Pancreatic Cancer |
title_short | Targeting Macrophage Migration Inhibitory Factor in Acute Pancreatitis and Pancreatic Cancer |
title_sort | targeting macrophage migration inhibitory factor in acute pancreatitis and pancreatic cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992011/ https://www.ncbi.nlm.nih.gov/pubmed/33776775 http://dx.doi.org/10.3389/fphar.2021.638950 |
work_keys_str_mv | AT wenyongjian targetingmacrophagemigrationinhibitoryfactorinacutepancreatitisandpancreaticcancer AT caiwenhao targetingmacrophagemigrationinhibitoryfactorinacutepancreatitisandpancreaticcancer AT yangjingyu targetingmacrophagemigrationinhibitoryfactorinacutepancreatitisandpancreaticcancer AT fuxianghui targetingmacrophagemigrationinhibitoryfactorinacutepancreatitisandpancreaticcancer AT puthalohitha targetingmacrophagemigrationinhibitoryfactorinacutepancreatitisandpancreaticcancer AT xiaqing targetingmacrophagemigrationinhibitoryfactorinacutepancreatitisandpancreaticcancer AT windsorjohna targetingmacrophagemigrationinhibitoryfactorinacutepancreatitisandpancreaticcancer AT phillipsanthonyr targetingmacrophagemigrationinhibitoryfactorinacutepancreatitisandpancreaticcancer AT tyndalljoelda targetingmacrophagemigrationinhibitoryfactorinacutepancreatitisandpancreaticcancer AT dudan targetingmacrophagemigrationinhibitoryfactorinacutepancreatitisandpancreaticcancer AT liutingting targetingmacrophagemigrationinhibitoryfactorinacutepancreatitisandpancreaticcancer AT huangwei targetingmacrophagemigrationinhibitoryfactorinacutepancreatitisandpancreaticcancer |